SOLVE FSHD Invests $3M in Altay Therapeutics to develop novel inhibitors for FSHD

​September 2022

​

We're are very excited to be working on first-in-class inhibitors for FSHD using our platform technology. SOLVE FSHD's investment will accelerate our drug development efforts and shorten the time to enter clinical trials. Read about it here.

​

Altay is awarded Golden Ticket by Bristol Myers Squibb!

November 2021

​

We're honored to have been selected as a Golden Ticket recipient by Bristol Myers Squibb! We look forward to working in MBC BioLabs to continue our work developing first-in-class inhibitors targeting previously undruggable transcription factors with the goal of advancing medicines and therapies that will ultimately save patient lives. Read about it here.

​

​FSHD Global invests in Altay

September 2021

​

We are delighted to share that FSHD Global has invested in Altay to further development of our anti-DUX4 program. Successful inhibition of DUX4 with small molecules will prevent muscle death leading to a better quality of life. We are honored to be in this fight with the friends of FSHD.

​

Altay is awarded grant  from Friends of FSH Research

​May 2021

​

We are delighted to share that Altay Therapeutics Inc. was awarded a grant from the Friends of FSH foundation to implement our platform for the discovery of small molecule inhibitors targeting transcription factor, DUX4. Upregulated expression of DUX4 leads to muscle cell death in patients suffering from facioscapulohumeral muscular dystrophy (FSHD). Successful inhibition of DUX4 with small molecules will prevent muscle death leading to a better quality of life. We are honored to be in this fight with the friends of FSHD.

​

Altay is accepted into Y-combinator's Winter 2020 batch!

January 2020

​

We are delighted to share that Altay Therapeutics Inc. was accepted into Y-combinator's Winter 2020 program to develop our platform technology and our fibrosis program!